Needle-Free Administration of Botulinum Toxin for Primary Focal Hyperhidrosis: Initial Experience
Clinical Dermatology Open Access Journal · 2017
DOI: 10.23880/cdoaj-16000131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Dermatology Open Access Journal, 2017. Verfasst von Artzi O.
Abstract (Originalsprache)
Local intradermal injections of botulinum toxin (BTX) effectively provide symptom relief of primary focal hyperhidrosis (PFHH), but they can be painful and a deterrent for repeated treatments.The EnerJet system delivers therapeutic substances into the dermis via a high-pressure liquid jet.In this proof-of-concept trial, BTX was administered by the EnerJet system without anesthesia.The pre-and 4 weeks' post-treatment disease severity and symptom burden were assessed [Hyperhidrosis Disease Severity Scale (HDSS), the Dermatology Life Quality Index (DLQI) and Minor starchiodine tests].All 11 patients had severe PFHH.The number of required shots ranged between 50-90 for the bilateral axillary areas and 75-100 for the palmar areas.Total reduction of DLQI and HDSS scores at 4 weeks post-EnerJet system treatment indicated improvement in symptom burden and quality of life.BTX delivery by the EnerJet system may be a simple and effective alternative to conventional BTX injections.
Zitieren
APA
O, A. (2017). Needle-Free Administration of Botulinum Toxin for Primary Focal Hyperhidrosis: Initial Experience. Clinical Dermatology Open Access Journal. https://doi.org/10.23880/cdoaj-16000131
Vancouver
O A. Needle-Free Administration of Botulinum Toxin for Primary Focal Hyperhidrosis: Initial Experience. Clinical Dermatology Open Access Journal. 2017. doi:10.23880/cdoaj-16000131
BibTeX
@article{O2017,
author = {O, Artzi},
title = {Needle-Free Administration of Botulinum Toxin for Primary Focal Hyperhidrosis: Initial Experience},
journal = {Clinical Dermatology Open Access Journal},
year = {2017},
doi = {10.23880/cdoaj-16000131}
}
EUVIMED